Recent Updates
Recently added Catalysts
JNJ Positive Sentiment

Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology

Key Takeaway: Johnson & Johnson has announced its acquisition of Ollin Biosciences for $2.2 billion. This clinical-stage biopharmaceutical company specializes in therapies for serious eye diseases. The deal includes potential additional payments based on regulatory and commercial milestones, indicating a strong commitment to advancing ophthalmology treatments.

Market Sentiment Analysis

POSITIVE FACTORS

  • Johnson & Johnson acquires Ollin Biosciences for $2.2 billion.
  • Acquisition focuses on therapies for serious eye diseases.
  • Potential for additional milestone payments enhances value.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+28%
120-day peak, hindsight
Typical move
1.7%
average across 15 past catalysts
Lead asset
JNJ-77242113
Phase 3 · Generalized Pustular Psoriasis

Full Press Release Details

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Ollin Biosciences, Inc., (“Ollin”) a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for $2.2 billion upfront, with the potential for additional regulatory and commercial milestone payments. Johnson & Johnson will also enter into a separate development funding agreement with Blackstone Life Sciences (“Blackstone

Frequently Asked Questions

What is the value of the acquisition?

Johnson & Johnson is acquiring Ollin Biosciences for $2.2 billion.

What does Ollin Biosciences specialize in?

Ollin Biosciences develops therapies for serious eye diseases.

Are there additional payments involved?

Yes, there are potential milestone payments based on regulatory and commercial success.

Who is partnering with Johnson & Johnson?

Johnson & Johnson will also work with Blackstone Life Sciences.

Last updated: Nov 16, 2026